<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Annals of the Russian academy of medical sciences</journal-id><journal-title-group><journal-title xml:lang="en">Annals of the Russian academy of medical sciences</journal-title><trans-title-group xml:lang="ru"><trans-title>Вестник Российской академии медицинских наук</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0869-6047</issn><issn publication-format="electronic">2414-3545</issn><publisher><publisher-name xml:lang="en">"Paediatrician" Publishers LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">2328</article-id><article-id pub-id-type="doi">10.15690/vramn2328</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>INTERNAL DISEASES: CURRENT ISSUES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>АКТУАЛЬНЫЕ ВОПРОСЫ ВНУТРЕННИХ БОЛЕЗНЕЙ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">MRI for Quantitative Determination of Iron in the Liver and Heart in Patients with Primary and Secondary Hemochromatoses in Association with Serrum Ferritin: Single-Stage Observational Study</article-title><trans-title-group xml:lang="ru"><trans-title>МРТ для количественного определения железа в печени и сердце у пациентов с первичными и вторичными гемохроматозами во взаимосвязи с ферритином сыворотки крови: одномоментное обсервационное исследование</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6605-0663</contrib-id><contrib-id contrib-id-type="spin">2243-6599</contrib-id><name-alternatives><name xml:lang="en"><surname>Titova</surname><given-names>Anna M.</given-names></name><name xml:lang="ru"><surname>Титова</surname><given-names>Анна Михайловна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD</p></bio><bio xml:lang="ru"><p>врач</p></bio><email>anisa33@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2937-6322</contrib-id><contrib-id contrib-id-type="spin">6072-3550</contrib-id><name-alternatives><name xml:lang="en"><surname>Fokin</surname><given-names>Vladimir A.</given-names></name><name xml:lang="ru"><surname>Фокин</surname><given-names>Владимир Александрович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Professor</p></bio><bio xml:lang="ru"><p>д.м.н., профессор</p></bio><email>vladfokin@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1611-5000</contrib-id><contrib-id contrib-id-type="spin">3139-3581</contrib-id><name-alternatives><name xml:lang="en"><surname>Trufanov</surname><given-names>Gennadii E.</given-names></name><name xml:lang="ru"><surname>Труфанов</surname><given-names>Геннадий Евгеньевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Professor</p></bio><bio xml:lang="ru"><p>д.м.н., профессор</p></bio><email>trufanovge@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5000-3582</contrib-id><name-alternatives><name xml:lang="en"><surname>Shalygina</surname><given-names>Ksenia S.</given-names></name><name xml:lang="ru"><surname>Шалыгина</surname><given-names>Ксения Сергеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Clinical Resident</p></bio><bio xml:lang="ru"><p>врач-ординатор</p></bio><email>shalygina_k98@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5751-6604</contrib-id><contrib-id contrib-id-type="spin">6788-0164</contrib-id><name-alternatives><name xml:lang="en"><surname>Tsvetkova</surname><given-names>Nadezhda V.</given-names></name><name xml:lang="ru"><surname>Цветкова</surname><given-names>Надежда Васильевна</given-names></name></name-alternatives><bio xml:lang="en"><p>Clinical Resident</p></bio><bio xml:lang="ru"><p>врач-ординатор</p></bio><email>nadya.cvetkova@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Almazov National Medical Research Centre</institution></aff><aff><institution xml:lang="ru">Национальный медицинский исследовательский центр имени В.А. Алмазова</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2023-03-04" publication-format="electronic"><day>04</day><month>03</month><year>2023</year></pub-date><volume>78</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>11</fpage><lpage>18</lpage><history><date date-type="received" iso-8601-date="2022-12-23"><day>23</day><month>12</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-02-03"><day>03</day><month>02</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2023, "Paediatrician" Publishers LLC</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2023, Издательство "Педиатръ"</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="en">"Paediatrician" Publishers LLC</copyright-holder><copyright-holder xml:lang="ru">Издательство "Педиатръ"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2024-03-04"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://vestnikramn.spr-journal.ru/jour/about/submissions</ali:license_ref></license></permissions><self-uri xlink:href="https://vestnikramn.spr-journal.ru/jour/article/view/2328">https://vestnikramn.spr-journal.ru/jour/article/view/2328</self-uri><abstract xml:lang="en"><p><bold><italic>Background. </italic></bold><italic>An extremely small number of studies have been devoted to the study of differences in LIC (liver iron concentration) and MIC (myocardium iron concentration) indicators, as well as their correlation with each other and with ferritin levels in patients with various nosological forms. <bold>Aims</bold> to study the relationship of ferritin, LIC and MIC levels in patients with various causes of hemochromatosis (hereditary hemochromatosis (HH), aplastic anemia (AA), primary myelofibrosis (PMF), thalassemia (TL), myelodysplastic syndrome (MDS)). <bold>Methods.</bold> The design of the study is a single–stage observational one. The study included 91 patients with primary hemochromatosis and secondary transfusion-dependent hemochromatosis receiving regular blood transfusion and iron chelate therapy from 2015 to 2018. The studies were carried out on 1.5 T MR-scanner Magnetom Espree (Siemens, Germany), and myocardial iron concentration (MIC) was calculated using the formula MIC = 45 × (T2*) – 1.22. Liver iron concentration (LIC) was calculated using the formula LIC = 0.03 × R2* + 0.74. The ferritin level was determined by enzyme immunoassay. Statistical processing of the results obtained was carried out using the SPSS software package. <bold>Results.</bold> Connections between LIC and ferritin (r = 0.867; p &lt; 0.001), MIC and ferritin (r = 0.759; p = 0.004) and LIC and MIC (r = 0.737; p = 0.006) were found in patients with primary hemochromatosis, while in patients with secondary hemochromatosis significant correlations were found only between LIC and MIC (r = 0.503; p &lt; 0.001), while the relationship was average. Links between LIC and ferritin were found in patients with AA (r = 0.656; p = 0.040), an average relationship, in patients with TL (r = 0.714; p = 0.020), an average relationship. The relationship between MIC and ferritin was revealed in patients with AA (r = 0.703; p = 0.050), an average relationship, in patients with TL (r = 0.757; p = 0.018), an average relationship. At the same time, in patients with MDS and PMF in this study, there was no association between ferritin and LIC, ferritin and MIC. <bold>Conclusions. </bold>In patients with hereditary hemochromatosis, LIC and MIC are associated with ferritin, and MIC is also associated with LIC (medium bond). In patients with iron overload due to thalassemia, an average correlation between LIC and ferritin, MIC and ferritin was revealed. In patients with iron overload due to aplastic anemia, an average correlation between LIC and ferritin, MIC and ferritin was revealed.</italic></p></abstract><trans-abstract xml:lang="ru"><p><bold><italic>Обоснование. </italic></bold><italic>Выполнено крайне небольшое количество исследований, посвященных изучению различий показателей концентрации железа в печени (liver iron concentration, </italic><italic>LIC</italic><italic>) и концентрации железа в миокарде (myocardium iron concentration, </italic><italic>MIC</italic><italic>), а также их корреляции между собой и с уровнем ферритина у пациентов с различными нозологическими формами. <bold>Цель исследования</bold> — изучение взаимосвязи уровня ферритина, LIC и MIC у пациентов с различными причинами гемохроматоза (наследственный гемохроматоз, апластическая анемия (АА), первичный миелофиброз (ПМФ), талассемия (ТЛ), миелодиспластический синдром (МДС)). <bold>Методы.</bold> Проведено одномоментное обсервационное исследование, в которое был включен 91 пациент с первичными гемохроматозами и вторичными трансфузионно-зависимыми гемохроматозами, получающие регулярное переливание крови и терапию хелаторами железа с 2015 по 2018 г. Исследование проводили на высокопольном томографе Siemens Magnetom Espree (Германия) с индукцией магнитного поля 1,5 Тл. Концентрацию железа в миокарде (MIC) рассчитывали по формуле MIC = 45 × (T2*) – 1,22, концентрацию железа в печени — по формуле LIC = 0,03 × R2* + 0,74. Уровень ферритина определялся с помощью иммуноферментного анализа. Статистическая обработка полученных результатов проводилась с использованием программного пакета SPSS. <bold>Результаты. </bold>Выявлены связи между LIC и ферритином (r = 0,867; p &lt; 0,001), MIC и ферритином (r = 0,759; p = 0,004) и LIC и MIC (r = 0,737; p = 0,006) у пациентов с первичным гемохроматозом, в то время как у пациентов со вторичным гемохроматозом значимые корреляции выявлены только между LIC и MIC (r = 0,503; p &lt; 0,001), при этом связь была средней. Выявлены средние связи между LIC и ферритином у пациентов с АА (r = 0,656; p = 0,040) и у пациентов с ТЛ (r = 0,714; p = 0,020). Выявлены средние связи между MIC и ферритином у пациентов с АА (r = 0,703; p = 0,050) и у пациентов с ТЛ (r = 0,757; p = 0,018). При этом у пациентов с МДС и ПМФ в данном исследовании не было выявлено связи между ферритином и LIC, ферритином и MIC. <bold>Заключение. </bold>У пациентов с наследственным гемохроматозом LIC и MIC связаны с ферритином, а также MIC связан с LIC (средняя связь). У пациентов с перегрузкой железом вследствие талассемии выявлена средняя связь между LIC и ферритином, MIC и ферритином. У пациентов с перегрузкой железом вследствие АА выявлена средняя связь между LIC и ферритином, MIC и ферритином.</italic></p></trans-abstract><kwd-group xml:lang="en"><kwd>primary hemochromatosis</kwd><kwd>aplastic anemia</kwd><kwd>thalassemia</kwd><kwd>LIC</kwd><kwd>MIC</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>первичный гемохроматоз</kwd><kwd>апластическая анемия</kwd><kwd>талассемия</kwd><kwd>LIC</kwd><kwd>MIC</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Chouliaras G, Berdoukas V, Ladis V, et al. Impact of magnetic resonance imaging on cardiac mortality in thalassemia major. J Magn Reson Imaging. 2011;34(1):56–59. doi: https://doi.org/10.1002/jmri.22621</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Golfeyz S, Lewis S, Weisberg IS. Hemochromatosis: pathophysiology, evaluation, and management of hepatic iron overload with a focus on MRI. Expert Rev Gastroenterol Hepatol. 2018;12(8):767–778. doi: https://doi.org/10.1080/17474124.2018.1496016</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Gandon Y, Olivié D, Guyader D, et al. Non-invasive assessment of hepatic iron stores by MRI. Lancet. 2004;363(9406):357–362. doi: https://doi.org/10.1016/S0140-6736(04)15436-6</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>St Pierre TG, Clark PR, Chua-anusorn W, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood. 2005;105(2):855–861. doi: https://doi.org/10.1182/blood-2004-01-0177</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22(23):2171–2179. doi: https://doi.org/.1053/euhj.2001.2822</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Carpenter JP, He T, Kirk P, et al. On T2* magnetic resonance and cardiac iron. Circulation. 2011;123(14):1519–1528. doi: https://doi.org/10.1161/CIRCULATIONAHA.110.007641</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Garbowski MW, Carpenter JP, Smith G, et al. Biopsy-based calibration of T2* magnetic resonance for estimation of liver iron concentration and comparison with R2 Ferriscan. J Cardiovasc Magn Reson. 2014;16(1):40. doi: https://doi.org/10.1186/1532-429X-16-40</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Chandarana H, Lim RP, Jensen JH, et al. Hepatic iron deposition in patients with liver disease: preliminary experience with breath-hold multiecho T2*-weighted sequence. AJR Am J Roentgenol. 2009;193(5):1261–1267. doi: https://doi.org/10.2214/AJR.08.1996</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Westphalen AC, Qayyum A, Yeh BM, et al. Liver fat: effect of hepatic iron deposition on evaluation with opposed-phase MR imaging. Radiology. 2007;242(2):450–455. doi: https://doi.org/10.1148/radiol.2422052024</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Carpenter JP, Grasso AE, Porter JB, et al. On myocardial siderosis and left ventricular dysfunction in hemochromatosis. J Cardiovasc Magn Reson. 2013;15(1):24. doi: https://doi.org/10.1186/1532-429X-15-24</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Gulati V, Harikrishnan P, Palaniswamy C, et al. Cardiac involvement in hemochromatosis. Cardiol Rev. 2014;22(2):56–68. doi: https://doi.org/10.1097/CRD.0b013e3182a67805</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Majd Z, Haghpanah S, Ajami GH, et al. Serum Ferritin Levels Correlation With Heart and Liver MRI and LIC in Patients With Transfusion-Dependent Thalassemia. Iran Red Crescent Med J. 2015;17(4):e24959. doi: https://doi.org/10.5812/ircmj.17(4)2015.24959</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Mandal S, Sodhi KS, Bansal D, et al. MRI for Quantification of Liver and Cardiac Iron in Thalassemia Major Patients: Pilot Study in Indian Population. Indian J Pediatr. 2017;84(4):276–282. doi: https://doi.org/10.1007/s12098-017-2310-8</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Killick SB, Bown N, Cavenagh J, et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol. 2016;172(2):187–207. doi: https://doi.org/10.1111/bjh.13853</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Porter J, Galanello R, Saglio G, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol. 2008;80(2):168–176. doi: https://doi.org/10.1111/j.1600-0609.2007.00985.x</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Zhang Q, Hou B, Wang L, et al. [Significance of magnetic resonance imaging in the detection of iron overload]. Zhonghua Yi Xue Za Zhi. 2013;93(44):3506–3509.</mixed-citation></ref></ref-list></back></article>
